Manas Mishra

A pharma journalist since 2017, Manas is interested in all aspects of the pharma industry and writes stories across all development phases. He may not look it, but he enjoys a mosh pit, is a beginner open-water swimmer, and loves sci-fi and fantasy.

Page 1 of 2

Trial Tuesday: The Slow Drift Out Of US Trials

The US still has the biggest market and the deepest regulatory expertise but early-stage sponsors are increasingly starting somewhere else.

Aug 18, 2026 Manas Mishra 4 min read members

A hand holds up a book whose cover reads "design:" against a plain wall.

Trial Tuesday: A Design Brief, A Heart Miss And A Restart

A melanoma advisory committee backs Replimune's RP-1 while pressing the field for better endpoints; Novo Nordisk's IL-6 inhibitor fails a 6,300-patient cardiovascular outcomes trial; and Rocket clears its first Danon disease patients under a revised protocol.

Aug 4, 2026 Manas Mishra 5 min read members

A person gestures with an open hand while talking at a table, an open laptop and a smartphone on a notebook beside them.

Trial Tuesday: Same Trial, Two Verdicts, As Deramiocel Meets The FDA Panel

Capricor and the FDA read HOPE-3 in opposite directions. Wednesday's committee decides which reading survives, with the agency's own call due August 22.

Jul 28, 2026 Manas Mishra 3 min read members

Hands clapping dust into the air, backlit against a dark background.

Trial Tuesday: Another Chronic Cough Program Bites The Dust

GSK's camlipixant failure marks the third P2X3 setback in chronic cough, wiping out the Phase III pipeline and leaving 2–3 million US patients with no branded option in sight.

Jul 21, 2026 Manas Mishra 3 min read members

Miniature brass Greek warriors mid-charge, one small fighter out front with spear and shield facing down the larger advance.

Trial Tuesday: MASH, KRAS And Keytruda's Copycat

A challenger in liver disease, a cancer head-to-head, and a biosimilar bet on doing the extra work. Each is wagering that the trial, not the head start, decides who wins.

Jul 7, 2026 Manas Mishra 6 min read members